SAVALnet – Science and Medicine

In an effort to improve specificity and reduce the incidence of false positives, while maintaining or increasing sensitivity, a Next generation stool DNA testing Of the many objectives that include assessments Molecular markers And levels Hemoglobin To detect Colorectal cancer.

In this prospective study called BLUE-C, Thomas F. Imperial and collaborators from Indiana University School of Medicine (USA) evaluated molecular testing in asymptomatic adults aged 40 years or older who underwent molecular screening. Colonoscopy a statement.

20,176 individuals with one molecular test participated Fecal immunohistochemistry (FIT). Both colorectal cancer sensitivity and specificity Advanced tumorsincluding Precancerous lesions Applicant: one or more Adenomas also Sessile toothed pests (at least 1 cm), lesions with villous histological features and Dysplasia A high degree.

Of the total participants, 98 had precancerous disease, 2144 had precancerous lesions, 6973 had nonadvanced adenomas, and 10961 had nonadenomas or negative colonoscopy findings. With DNA testing, sensitivity for colorectal cancer and advanced precancerous lesions was 93.9% and 43.4% (95% CI), respectively; The specificity for advanced tumors and non-neoplastic findings or negative colonoscopy was 90.6% and 92.7% (95% CI), respectively. With FIT, sensitivity for colorectal cancer and advanced precancerous lesions was 67.3% and 23.3% (95% CI), respectively; The specificity for advanced tumors and non-neoplastic findings or negative colonoscopy was 94.8% and 95.7% (95% CI), respectively.

In conclusion, the new version of the multi-target stool DNA test showed greater sensitivity in detecting colorectal cancer and advanced precancerous lesions versus fecal immunohistochemistry, however, specificity was lower in advanced tumors.